Oric Pharmaceuticals Inc. (ORIC) News
Filter ORIC News Items
ORIC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ORIC News Highlights
- For ORIC, its 30 day story count is now at 2.
- Over the past 6 days, the trend for ORIC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- VIEW are the most mentioned tickers in articles about ORIC.
Latest ORIC News From Around the Web
Below are the latest news stories about ORIC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ORIC as an investment opportunity.
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination DevelopmentPreliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose limiting toxicities or dose reductions Clinical activity, safety profile, and dose-dependent increases in immune cell activation support potential for combination studies with other multiple myeloma agents, including BCMA- and CD38-directed therapies Company to pursue strategic partne |
3 Stocks at the Forefront of Personalized Medicine TrendUnveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly |
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on December 1, 2023 (the “Grant Date”), ORIC granted a total of 23,080 non-qualified stock options and 3,840 restricted stock units to three new non-executive employees who began their employment with ORIC in November 2023. These inducement g |
ORIC Pharmaceuticals to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in November: Jefferies London Healthcare Conference – Participating in a fireside chat on Thursday, November 16, 2023, at 10:00 a.m. GMT6th Annual Evercore ISI HealthCONx Conference – |
ORIC Pharmaceuticals Inc (ORIC) Reports Q3 2023 Financial Results and Operational UpdatesORIC's Cash and Investments Reach $256.2 Million, R&D Expenses Increase to $22.4 Million |
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational UpdatesPresented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile Initial Phase 1b data for ORIC-533 in patients with multiple myeloma to be presented at the 65th ASH Annual Meeting being held December 9-12, 2023 Initial Phase 1b data for ORIC-944 in patients with prostate cancer expected in first quarter of 2024 Cash and investments of $256.2 million expected to fund operating plan into late 2025 SOUTH SAN FRANCISCO a |
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. Indeed, ORIC Pharmaceuticals... |
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation on the initial Phase 1b clinical data for ORIC-533 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023, in San Diego, CA. Details of |
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class ProfileCNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dose levels in heavily pre-treated NSCLC patients, characterized by 81% having received prior EGFR exon 20 targeted agents and 86% having CNS metastases at baseline At potential RP2D of 75 mg QD, responses observed in 2 of 3 EGFR exon 20 patients previously treated w |
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated cancersSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present two poster presen |